keyword
MENU ▼
Read by QxMD icon Read
search

Yttrium 90

keyword
https://www.readbyqxmd.com/read/29052747/angiosomal-radiopathologic-analysis-of-transarterial-radioembolization%C3%A2-for-the-treatment-of-hepatocellular-carcinoma
#1
Altan F Ahmed, Naziya Samreen, Joseph R Grajo, Ivan Zendejas, Chris L Sistrom, Amy Collinsworth, Ashwini Esnakula, Jehan L Shah, Roniel Cabrera, Brian S Geller, Beau B Toskich
PURPOSE: To assess the radiopathologic correlation following Yttrium-90 transarterial radioembolization (TARE) of hepatocellular carcinoma (HCC) using variable radiodosimetry to identify imaging surrogates of histologic response. METHODS: Twelve patients with HCC underwent ablative (≥ 190 Gy) and/or non-ablative (< 190 Gy) TARE delivered in a segmental, lobar, or combined fashion as a surgical neoadjuvant or bridge to transplantation. Both targeted tumor and treatment angiosome were analyzed before and after TARE utilizing hepatocyte-specific contrast-enhanced MRI or contrast-enhanced CT...
October 20, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/29049048/urinary-excretion-of-yttrium-90-after-radioembolization-with-yttrium-90-labeled-resin-based-microspheres
#2
Oliver S Grosser, Juri Ruf, Annette Pethe, Dennis Kupitz, Heiko Wissel, Christoph Benckert, Maciej Pech, Jens Ricke, Holger Amthauer
In radioembolic therapy (RET) of hepatic malignancies using yttrium-90 (Y)-labeled resin microspheres, radiation protection is primarily concerned with avoiding contamination by radioactive spheres. However, as Y is bound to the microsphere surface by a potentially reversible ion-exchange process, the aim of this study was to assess the extent of the potential excreted activity in urine. After RET with Y-labeled resin-based microspheres, urinary excretion of free Y was prospectively analyzed in 51 interventions (n = 45 patients) by sampling urine over 48 h (two 24-h intervals) consecutively...
October 18, 2017: Health Physics
https://www.readbyqxmd.com/read/29033589/yttrium-90-radioembolization-of-unresectable-hepatocellular-carcinoma-a-single-center-experience
#3
Carsten Meyer, Claus Christian Pieper, Hojjat Ahmadzadehfar, Nina Alexandra Lampe, Eva Maria E Matuschek, Thomas Adrian Maschke, Simon Jonas Enkirch, Markus Essler, Ulrich Spengler, Hans Heinz Schild
PURPOSE: To determine the value of radioembolization (RE) for treatment of unresectable hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Records of patients undergoing RE for unresectable HCC were retrospectively reviewed. Biochemical and clinical toxicities, imaging response (according to modified Response Evaluation Criteria In Solid Tumors), time-to-progression (TTP) and overall survival (OS) were analyzed. Data were stratified according to clinical and procedural parameters...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29028102/the-ten-commandments-of-hepatic-radioembolization-expert-discussion-and-report-from-mediterranean-interventional-oncology-miolive-congress-2017
#4
J L Bilbao, R Iezzi, S N Goldberg, A Sami, O Akhan, F Giuliante, M Pompili, L Crocetti, K Malagari, V Valentini, A Gasbarrini, C Colosimo, R Manfredi
Microsphere and particle technology represent the next-generation agents that have formed the basis of interventional oncology, an evolving subspecialty of interventional radiology. One of these platforms, yttrium-90 microspheres, is increasingly being used as a treatment modality for primary and secondary liver tumors. Due to the widespread use of radioembolization, a comprehensive review of the methodologic and technical considerations seems to be mandatory. This article summarizes the expert discussion and report from Mediterranean Interventional Oncology Live Congress (MIOLive 2017) that was held in Rome, Italy, integrating evidence-reported literature and experience-based perceptions, to assist not only residents and fellows who are training in interventional radiologists but also practicing colleagues who are approaching to this intra-arterial treatment...
September 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28990969/dosimetry-in-radiosynoviorthesis-90y-vs-153sm
#5
Mirta Barbara Torres Berdeguez, Sylvia Thomas, Susie Medeiros, Lidia Vasconcellos de Sá, Felix Mas Milian, Ademir Xavier da Silva
Although there are several radionuclides suitable for radiosynoviorthesis (RSO), not all of them can irradiate deeper synovium. Yttrium-90 (Y) is the beta radionuclide with more penetration range; therefore, it is predominantly used to treat knees. The aim of this paper is to highlight several dosimetry concepts to compare Y and Sm, also discussing the feasibility of implementing a dose planning methodology for both in RSO. The MCNPX Monte Carlo nuclear code version 2.6 was used for calculating S-values from which the activity to be injected into the joint was obtained...
October 5, 2017: Health Physics
https://www.readbyqxmd.com/read/28989121/protective-effect-of-adhesive-systems-associated-with-neodymium-doped-yttrium-aluminum-garnet-laser-on-enamel-erosive-abrasive-wear
#6
Erica Crastechini, Alessandra B Borges, Klaus Becker, Thomas Attin, Carlos Rg Torres
AIM: This study evaluated the efficacy of self-etching adhesive systems associated or not associated with the neodymium-doped yttrium aluminum garnet (Nd:YAG) laser on the protection against enamel erosive/abrasive wear. MATERIALS AND METHODS: Bovine enamel specimens were demineralized with 0.3% citric acid (5 minutes). The samples were randomly assigned to eight groups (n = 20): SB - Single Bond Universal (3M/ESPE); SB+L - Single Bond Universal + laser (80 mJ/10 Hz); FB - Futurabond U (Voco); FB+L -Futurabond U + laser; GEN - G-aenial bond (GC); GEN+L -G-aenial bond + laser; L - laser irradiation; and C - no treatment...
October 1, 2017: Journal of Contemporary Dental Practice
https://www.readbyqxmd.com/read/28987953/a-novel-bioelectrochemical-system-for-chemical-free-permanent-treatment-of-acid-mine-drainage
#7
Guillermo Pozo, Sebastien Pongy, Jürg Keller, Pablo Ledezma, Stefano Freguia
The mining sector is currently under unprecedented pressure due to stringent environmental regulations. As a consequence, a permanent acid mine drainage (AMD) treatment is increasingly being regarded as a desirable target with direct benefits for the environment and the operational and economic viability of the resources sector. In this study we demonstrate that a novel bioelectrochemical system (BES) can deliver permanent treatment of acid mine drainage without chemical dosing. The technology consists of a two-cell bioelectrochemical setup to enable the removal of sulfate from the ongoing reduction-oxidation sulfur cycle to less than 550 mg L(-1) (85 ± 2% removal from a real AMD of an abandoned silver mine), thereby also reducing salinity at an electrical energy requirement of 10 ± 0...
September 30, 2017: Water Research
https://www.readbyqxmd.com/read/28984155/cancer-directed-therapy-and-potential-impact-on-survivals-in-nonresected-hepatocellular-carcinoma-seer-medicare-population-study
#8
Nima Kokabi, Richard Duszak, Minzhi Xing, David H Howard, Kimberly E Applegate, Juan C Camacho, Hyun S Kim
AIM: To investigate determinants of receiving cancer-directed therapies and their potential survival impact in nonresected hepatocellular carcinoma (HCC) Materials & methods: Nonsurgically resected HCC patients between 2000 and 2010 were stratified by American Joint Committee on Cancer staging and the type of therapy. Predictors of receiving therapy were identified and implication on survival was evaluated. RESULTS: Out of 9239 patients included, those receiving any therapy demonstrated prolonged overall survival with following median overall survival (months): ablation (30...
October 6, 2017: Future Oncology
https://www.readbyqxmd.com/read/28931854/robust-magnon-photon-coupling-in-a-planar-geometry-hybrid-of-inverted-split-ring-resonator-and-yig-film
#9
Biswanath Bhoi, Bosung Kim, Junhoe Kim, Young-Jun Cho, Sang-Koog Kim
We experimentally demonstrate strongly enhanced coupling between excited magnons in an Yttrium Iron Garnet (YIG) film and microwave photons in an inverted pattern of split-ring resonator (noted as ISRR). The anti-crossing effects of the ISRR's photon mode and the YIG's magnon modes were found from |S21|-versus-frequency measurements for different strengths and directions of externally applied magnetic fields. The spin-number-normalized coupling strength (i.e. single spin-photon coupling) [Formula: see text] was determined to 0...
September 20, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28916345/is-a-technetium-99m-macroaggregated-albumin-scan-essential-in-the-workup-for-selective-internal-radiation-therapy-with-yttrium-90-an-analysis-of-532-patients
#10
Lidia Sancho, Macarena Rodriguez-Fraile, Jose Ignacio Bilbao, Carmen Beorlegui Arteta, Mercedes Iñarrairaegui, Veronica Moran, Bruno Sangro
PURPOSE: To determine if baseline patient, tumor, and pretreatment evaluation characteristics could help identify patients who require technetium-99m ((99m)Tc) macroaggregated albumin ((99m)Tc MAA) imaging before selective internal radiation therapy (SIRT). MATERIALS AND METHODS: In this retrospective analysis, 532 consecutive patients with primary (n = 248) or metastatic (n = 284) liver tumors were evaluated between 2006 and 2015. Variables were compared between patients in whom (99m)Tc MAA imaging results contraindicated/modified SIRT administration with yttrium-90 ((90)Y) resin microspheres and those who were treated as initially planned...
September 13, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/28902765/low-dose-90y-pet-ct-imaging-optimized-for-lesion-detectability-and-quantitative-accuracy-a-phantom-study-to-assess-the-feasibility-of-pretherapy-imaging-to-plan-the-therapeutic-dose
#11
Maryam Khazaee, Alireza Kamali-Asl, Parham Geramifar, Arman Rahmim
OBJECTIVE: The overall aim of this work is to optimize the reconstruction parameters for low-dose yttrium-90 (Y) PET/CT imaging, and to determine Y minimum detectable activity, in an endeavor to investigate the feasibility of performing low-dose Y imaging in-vivo to plan the therapeutic dose in radioembolization. MATERIALS AND METHODS: This study was carried out using a Siemens Biograph 6 True Point PET/CT scanner. A Jaszczak phantom containing five hot syringes was imaged serially over 15 days...
November 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28900709/pretransplant-intra-arterial-liver-directed-therapy-does-not-increase-the-risk-of-hepatic-arterial-complications-in-liver-transplantation-a-single-center-10-year-experience
#12
Joseph R Kallini, Ahmed Gabr, Rehan Ali, Nadine Abouchaleh, Ahsun Riaz, Talia Baker, Laura Kulik, Juan Caicedo, Riad Salem, Robert J Lewandowski
PURPOSE: To investigate the association between pretransplant intra-arterial liver-directed therapy (IAT) for hepatocellular carcinoma (HCC) and hepatic arterial complications (HAC) in orthotopic liver transplantation (OLT) [namely hepatic artery thrombosis (HAT) and/or the need for hepatic arterial conduit]. METHODS: A total of 175 HCC patients (mean age: 60 years) underwent IAT with either transarterial chemoembolization or yttrium-90 (90Y) transarterial radioembolization prior to OLT between 2003 and 2013...
September 12, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28894793/infiltrative-hepatocellular-carcinoma-with-portal-vein-tumor-thrombosis-treated-with-a-single-high-dose-y90-radioembolization-and-subsequent-liver-transplantation-without-a-recurrence
#13
Meaghan S Dendy, Juan C Camacho, Johannes M Ludwig, Alyssa M Krasinskas, Stuart J Knechtle, Hyun S Kim
BACKGROUND: Infiltrative hepatocellular carcinoma with macrovascular invasion is a relatively rare presentation and usually fatal disease. METHODS: Both patients exceeded Milan and University of California-San Francisco (UCSF) criteria, and per Barcelona Clinic Liver Cancer group guidelines, they were enrolled in a prospective open-label radioembolization phase II trial that gave them optimized lobar doses of Yttrium-90 as solely the first-line therapy without concomitant or additional pharmacological or locoregional therapies...
September 2017: Transplantation Direct
https://www.readbyqxmd.com/read/28890809/a-single-institute-retrospective-trial-of-concurrent-chemotherapy-with-sir-spheres-%C3%A2-versus-sir-spheres-%C3%A2-alone-in-chemotherapy-resistant-colorectal-cancer-liver-metastases
#14
May Cho, Jonathan Kessler, John J Park, Aram Lee, Jun Gong, Gagandeep Singh, Yi-Jen Chen, Philip H G Ituarte, Marwan Fakih
BACKGROUND: The use of selective internal radiation therapy with yttrium 90 resin microspheres (SIR-Spheres(®)) in chemotherapy-resistant colorectal cancer liver metastases has been associated with favorable progression-free survival (PFS) and overall survival when given alone or concurrently with chemotherapy. We conducted a single institute retrospective trial to explore the potential impact of SIR-Spheres(®) with concurrent chemotherapy vs. SIR-Spheres(®) alone on liver PFS in patients with colorectal liver metastases (CRLM)...
August 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28888827/tumor-dose-response-in-yttrium-90-resin-microsphere-embolization-for-neuroendocrine-liver-metastases-a-tumor-specific-analysis-with-dose-estimation-using-spect-ct
#15
Orapin Chansanti, Younes Jahangiri, Yusuke Matsui, Akira Adachi, Yindee Geeratikun, John A Kaufman, Kenneth J Kolbeck, Jeffrey S Stevens, Khashayar Farsad
PURPOSE: To evaluate dose-response relationship in yttrium-90 ((90)Y) resin microsphere radioembolization for neuroendocrine tumor (NET) liver metastases using a tumor-specific dose estimation based on technetium-99m-labeled macroaggregated albumin ((99m)Tc MAA) single photon emission computed tomography (SPECT)-CT. MATERIALS AND METHODS: Fifty-five tumors (mean size 3.9 cm) in 15 patients (10 women; mean age 57 y) were evaluated. Tumor-specific absorbed dose was estimated using a partition model...
September 6, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/28881497/therapies-for-advanced-stage-hepatocellular-carcinoma-with-macrovascular-invasion-or-metastatic-disease-a-systematic-review-and-meta-analysis
#16
REVIEW
Richard S Finn, Andrew X Zhu, Farah Wigdan, Jehad Almasri, Feras Zaiem, Larry J Prokop, Mohammad Hassan Murad, Khaled Mohammed
Hepatocellular carcinoma (HCC) is a complex disease most commonly arising in the background of chronic liver disease. In the past two decades there has been a significant increase in our understanding of both the clinical and molecular heterogeneity of HCC. There has been a robust increase in clinical trial activity in patients with poor prognostic factors such as macrovascular invasion and extrahepatic spread. We aimed to synthesize the evidence for the treatment of patients with advanced HCC based on these baseline characteristics including patients with both Child-Pugh scores of A and B...
September 7, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28879621/survival-analysis-of-advanced-hcc-treated-with-radioembolization-comparing-impact-of-clinical-performance-status-versus-vascular-invasion-metastases
#17
Rehan Ali, Ahmed Gabr, Nadine Abouchaleh, Ali Al Asadi, Ronald A Mora, Laura Kulik, Michael Abecassis, Ahsun Riaz, Riad Salem, Robert J Lewandowski
PURPOSE: In this study, we aim to compare the effects of prognostic indicators on survival analysis for Barcelona Clinic Liver Cancer (BCLC) C patients undergoing yttrium-90 radioembolization (Y-90). METHODS: A prospectively acquired database (2003-2017) for BCLC C hepatocellular carcinoma (HCC) patients that underwent radioembolization with Y-90 was searched. The criteria for BCLC C status (Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 1 or 2, metastases, and/or portal vein thrombosis (PVT)) were recorded...
September 6, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28875374/yttrium-90-radioembolization-treatment-for-unresectable-hepatocellular-carcinoma-a-single-centre-prognostic-factors-analysis
#18
C Floridi, F Pesapane, S A Angileri, D De Palma, F Fontana, F Caspani, A Barile, A Del Sole, C Masciocchi, G Lucignani, G Carrafiello
The aim of this study was to evaluate the efficacy and the safety of Y90 radioembolization (Y90-RE) in patients with unresectable hepatocellular carcinoma (HCC) analysing our results and correlating them with independent prognostic factors for overall survival (OS) and for complications. Forty-three patients with advanced inoperable HCC including those with multiple bilobar lesions or portal vein thrombosis (PVT) treated with Y90-RE were reviewed. Treatment efficacy and safety were evaluated. Survival was calculated by the Kaplan-Meier method...
September 5, 2017: Medical Oncology
https://www.readbyqxmd.com/read/28869617/a-phase-1-trial-of-90-y-zevalin-radioimmunotherapy-with-autologous-stem-cell-transplant-for-multiple-myeloma
#19
A Dispenzieri, A D'Souza, M A Gertz, K Laumann, G Wiseman, M Q Lacy, B LaPlant, F Buadi, S R Hayman, S K Kumar, D Dingli, W J Hogan, S M Ansell, D A Gastineau, D J Inwards, I N Micallef, L F Porrata, P B Johnston, M R Litzow, T E Witzig
This phase 1 study (clinical trial NCT00477815) was conducted to determine the maximum tolerated dose (MTD) of yttrium-90 ibritumomab tiuxetan ((90)Y-Zevalin) with high dose melphalan (HDM) therapy in multiple myeloma (MM) patients undergoing autologous stem cell transplantation (ASCT). In a 3+3 trial design, 30 patients received rituximab 250 mg/m(2) with indium-111 ibritumomab tiuxetan ((111)In-Zevalin) for dosimetry (day -22); rituximab 250 mg/m(2) with escalating doses of (90)Y-Zevalin (day -14); melphalan 100 mg/m(2) (days -2,-1) followed by ASCT (day 0) and sargramostim (GM-CSF, day 0) until neutrophil engraftment...
October 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28868022/successful-yttrium-90-microsphere-radioembolization-for-hepatic-metastases-of-prostate-cancer
#20
Alexander C Bunck, Daniel Pinto Dos Santos, De-Hua Chang, Marcel Reiser, David Pfister, Anne Bunck, Alexander Drzezga, David Maintz, Matthias Schmidt
Prostate cancer is the most common solid tumor malignancy worldwide with an estimated 180,000 new cases of prostate cancer and 26,000 deaths in the USA in 2016. Although significant advances in the treatment of prostate cancer have recently been made, the treatment of metastatic disease remains a challenge. With visceral metastases marking more advanced tumor stages, liver involvement is associated with the worst prognosis. So far, no locoregional treatment regimens for the management of liver metastases of prostatic cancer exist...
May 2017: Case Reports in Oncology
keyword
keyword
8545
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"